Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Recurrence × vocimagene amiretrorepvec × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 2 Astrocytoma 2 Recurrence 1 Oligodendroglioma 1

Interventions

Temozolomide 3 Etoposide 3 pembrolizumab 2 Lomustine 2 Haloperidol 2 Gemcitabine 2 Cyclosporine 2 vocimagene amiretrorepvec 1 trofosfamide 1 ruxolitinib 1 regorafenib 1 peginterferon alfa-2b 1 osimertinib 1 interferon gamma-1b 1 interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1 imetelstat 1 glumetinib 1 etoposide phosphate 1 eculizumab 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 carbon-11 acetate 1 auricularum 1 aldesleukin 1 Thiotepa 1 Sirolimus 1 Rituximab 1 Radiation 1 Peripheral Blood Stem Cell Transplantation 1 Pemetrexed 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡